landiolol hydrochloride

landiolol hydrochloride (RAPIBLYK) is an FDA-listed pharmaceutical active ingredient. Route of administration: intravenous. Current US regulatory status: approved.

RAPIBLYK is a marketed brand name for landiolol hydrochloride. Check FDA Drugs@FDA for the current US label holder and prescribing information.

landiolol hydrochloride has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.